ARCHIVES

MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.

This article is from The Cancer Letter archive.

Vol. 27 No. 09 | March 2, 2001

Download PDF Visit The Full Archive

Related Articles

Preoperative Chemo Doubles Survival In Locally Advanced Bladder Cancer

May 25, 2001

Natural Product Drug Discovery Groups Receive Concept Approval

February 26, 1988

In Brief: FDA Changes Package Inserts For Thiotepa, Cyclophosphamide, As Committee Suggested

August 31, 1979

Centers’ Problems Get Increasing Attention From Staff, Advisors

August 20, 1976

RPR Grant To NABCO Does Not Support Advocacy, Firm Says

November 10, 1995

In Brief: Healy Names President, CEO of Red Cross; AMA Supports annual Mammograms for 40+

July 16, 1999